Therapy, Maintenance, and Relapsed/Refractory Sequencing

This week, we kick off the first of our myeloma capstone roundtable discussions with two experts who treat myeloma every single day. We welcome back Dr. Manni Mohyuddin from the Huntsman Cancer Institute at the University of Utah, and introduce a new friend of the show, Dr. Adeel Khan from UT Southwestern. In part two, we cover three practical and rapidly evolving topics: the role of MRD testing in guiding treatment decisions, how to individualize maintenance therapy in 2026, and how to approach sequencing of CAR-T and bispecific therapies in the relapsed/refractory setting.

In this week’s show notes, we summarize the key thoughts about how our experts think about approach to their patients.

If you have not already done so, be sure to check out Part 1 of this discussion!

Content:

- What are the practical implications of MRD-testing in myeloma treatment?

- How do we think about maintenance therapy in the present day?

- What therapies are on the horizon?

- How do we approach management of younger patients with relapsed/refractory disease?

- How do we approach bridging therapy?

** This episode is sponsored by Primum! To learn more, sign up for your free account, and to ask questions to Primum experts, visit primum.co/fellows. As a special bonus, one of our guests, Dr. Mohyuddin, is an expert on Primum ready for your questions!

** Want to review the show notes for this episode and others? Check out our website.

Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Youtube

Episode 153: Myeloma Capstone, Pt 2 - MRD-Guided Therapy, Maintenance, and Relapsed/Refractory Sequencing

The Fellow on Call: The Heme/Onc Podcast

Episode 153: Myeloma Capstone, Pt 2 - MRD-Guided Therapy, Maintenance, and Relapsed/Refractory Sequencing